Ara-C suppresses H3 K27–altered spinal cord diffuse midline glioma growth and enhances immune checkpoint blockade sensitivity
Open Access
- 18 April 2025
- journal article
- cancer
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (16) , eadu3956
Abstract
H3 K27–altered spinal cord diffuse midline glioma (H3-SCDMG) poses therapeutic challenges. Analysis of 73 clinical samples revealed heightened proliferation in H3-SCDMG versus wild-type tumors, suggesting therapeutic vulnerabilities. Drug screening identified cytarabine (Ara-C) as highly effective in inhibiting proliferation in H3 K27M cell models, recently established patient-derived cells, and patient-derived xenograft models. Mechanistically, Ara-C can suppress tumor growth through DNA damage, cell-cycle arrest, and apoptosis. An investigator-initiated clinical trial involving four patients showed benefits in three cases. In addition, a subset of cells exhibited senescence and senescence-associated secretory phenotype post–Ara-C treatment, accompanied by several immune checkpoint ligands’ up-regulation and more immune cell infiltration. Combining Ara-C with dual Programmed cell death protein 1 (PD-1) and TIGIT blockade emerged as a promising strategy to disrupt immune evasion by senescent cells, enhancing antitumor responses. These findings highlight Ara-C’s potential as a monotherapy and in synergy with immunotherapy for H3-SCDMG, offering potential strategies for clinical management.Keywords
This publication has 47 references indexed in Scilit:
- Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine gliomaEBioMedicine, 2019
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapiesNature Reviews Drug Discovery, 2019
- Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid LeukaemiaDrugs, 2018
- Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapyNeuro-Oncology, 2018
- Non-inflammatory tumor microenvironment of diffuse intrinsic pontine gliomaActa Neuropathologica Communications, 2018
- Understanding the tumor immune microenvironment (TIME) for effective therapyNature Medicine, 2018
- Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seqScience, 2018
- EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomasNature Medicine, 2017
- Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric GlioblastomaScience, 2013
- Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumoursThe Lancet Oncology, 2010